VYC ‐17. 5L is Safe and Effective in Improving Skin Quality and Volume Deficit of Hands: Results From an 18‐Month Open‐Label Study
Year: 2026
Type: article
Study design: Clinical Trial
Abstract: BACKGROUND: Hands undergo age-related changes in volume and skin quality. This 18-month exploratory study evaluated safety and effectiveness of VYC-17.5 L for hand rejuvenation. METHODS: Participants (≥ 35 years) with moderate-to-extreme Allergan Hand Volume Deficit Scale (AHVDS) scores received VYC-17.5L in both hands on day 1, with optional touch-up on day 30. Effectiveness was assessed by AHVDS responder rate (≥ 1-grade improvement from baseline per hand) at months 1, 3 (primary effectiveness timepoint), and at 3-month intervals through month 18; investigator- and participant-Global Aesthetic Improvement Scale (GAIS); hand Self-Perception of Age (SPA); and skin quality measurements. Safety was evaluated throughout. RESULTS: Seventy-five participants (94.7% female; mean age, 53.89 years) had both hands injected with VYC-17.5L (median, 2.0 mL/hand), and 60.0% of hands received touch-up (median, 1.0 mL/hand). The primary endpoint was met: 100.0% of hands were AHVDS responders at month 3. The 100% response rate was maintained through month 6, and the majority of participants (> 65%) were responders through month 18. Most hands (≥ 85%) improved on investigator- and participant-GAIS through month 12. SPA improved by 5 to 6 years. Significant skin quality improvements persisted to 12 months. Twenty-two (29.3%) participants experienced treatment-related adverse events; most were mild or moderate in severity with a mean duration of 45.1 days, and none led to study discontinuation. CONCLUSION: VYC-17.5L is an effective treatment for improving hand volume deficit, with aesthetic benefits lasting 18 months.
Source: Journal of Cosmetic Dermatology
DOI: 10.1111/jocd.70675
Authors: Daniela Greiner‐Krüger, Christophe Leys, Sylwia Lipko‐Godlewska, Graeme M. Kerson, Smita Chawla, Carola de la Guardia
Institutions: Allergan (United Kingdom), AbbVie (Spain)
Language: English
Subfield: Dermatology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $3,020
Funders: Allergan Aesthetics, Allergan
OpenAlex ID: W7129074580
